SCHEDULE: Deep Track Capital Exits IMAGENEBIO Stake

Deep Track Capital and its affiliates have reported a complete divestment of their beneficial ownership in IMAGENEBIO, Inc. common stock.

Summary

• Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin filed an Amendment No. 1 to Schedule 13G for IMAGENEBIO, INC.
• The filing indicates that the reporting persons beneficially own 0 shares of IMAGENEBIO, INC. common stock, representing 0% of the class.
• This suggests a complete divestment of their previous stake in the company.
• The beneficial ownership calculation is based on 11,181,672 Common Stock outstanding as of November 3, 2025, as reported in IMAGENEBIO's 10-Q filed on November 12, 2025.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative signal for IMAGENEBIO, Inc. as a significant institutional investor has completely divested its stake, potentially indicating a loss of confidence.

Negatives

• Deep Track Capital, a significant institutional investor, has reduced its beneficial ownership in IMAGENEBIO, INC. to 0%.
• This complete divestment could signal a lack of confidence in the company's future prospects from a notable investor.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that institutional investor divestments, particularly from specialized funds like Deep Track Capital in the biotechnology sector, can sometimes precede or coincide with shifts in market sentiment or company-specific challenges. While not explicitly stated, such an exit might prompt other investors to re-evaluate their positions in IMAGENEBIO, Inc. or similar small-cap biotech firms.

Stakeholder Impact

• Shareholders: Existing shareholders may view the divestment by Deep Track Capital as a negative signal, potentially leading to downward pressure on the stock price.
• Potential Investors: New investors might be deterred by the exit of a specialized fund, prompting further due diligence.

Key Dates

Recommendation

The complete divestment by a specialized institutional investor like Deep Track Capital, as indicated by their 0% beneficial ownership in this Schedule 13G/A filing, suggests a significant loss of confidence in IMAGENEBIO, INC.'s future prospects. This action by a sophisticated market participant often signals underlying concerns that could lead to further stock price depreciation, making a 'sell' recommendation prudent for investors currently holding the stock.

Keywords

IMAGENEBIO, Deep Track Capital, Schedule 13G, Beneficial Ownership, Divestment, Common Stock, Biotechnology, Investment Fund